Latest Information Update: 28 May 2003
At a glance
- Originator Neurotech SA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Retinal disorders
Most Recent Events
- 28 May 2003 Discontinued - Preclinical for Retinal disorders in USA (Intraocular)
- 08 Oct 2001 New profile
- 08 Oct 2001 Preclinical development for Retinal disorders in USA (Intraocular)